Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

MK 0677

Known as: MK 677, MK-0677, MK-677 
 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

ibutamoren mesylate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Growth hormone secretagogues and growth hormone releasing peptides act as orthosteric super-agonists but not allosteric regulators for activation of the G protein Galpha(o1) by the Ghrelin receptor.
Some growth hormone secretagogues act as agonists at the ghrelin receptor and have been described as "ago-allosteric" ligands… Expand
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Nonpeptide and peptide growth hormone secretagogues act both as ghrelin receptor agonist and as positive or negative allosteric modulators of ghrelin signaling.
Two nonpeptide (L692,429 and MK-677) and two peptide [GH-releasing peptide (GHRP)-6 and ghrelin] agonists were compared in… Expand
Is this relevant?
2004
2004
The effects of MK-0677, an oral growth hormone secretagogue, in patients with hip fracture.
OBJECTIVES To evaluate the effects of MK-0677, an orally active growth hormone (GH) secretagogue, on functional recovery from hip… Expand
Is this relevant?
1999
1999
Increases in circulating insulin-like growth factor I levels by the oral growth hormone secretagogue MK-0677 in the beagle are dependent upon pituitary mediation.
It has been well established that the spiroindoline sulfonamide MK-0677 stimulates GH secretion from the pituitary both in vitro… Expand
Is this relevant?
1998
1998
Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males.
The effect of 2 months of treatment with the oral growth hormone (GH) secretagogue MK-677 on markers of bone metabolism was… Expand
Is this relevant?
1998
1998
The nonpeptide growth hormone secretagogue, MK-0677, activates hypothalamic arcuate nucleus neurons in vivo.
There is accumulating evidence that the hypothalamic arcuate nucleus plays an important role in mediating the effects of growth… Expand
Is this relevant?
Highly Cited
1998
Highly Cited
1998
Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.
Obesity is associated with blunted GH secretion, unfavorable body composition, and increased cardiovascular mortality. The… Expand
Is this relevant?
1998
1998
MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism.
The reversal of diet-induced negative nitrogen balance by GH suggests a possible therapeutic role for GH treatment in catabolic… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
1997
1997
Repeat administration of the GH secretagogue MK-0677 increases and maintains elevated IGF-I levels in beagles.
We have reported that MK-0677 is a novel, orally active GH secretagogue that stimulates an immediate and long-lasting increase in… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
1996
1996
MK-0677, a potent, novel, orally active growth hormone (GH) secretagogue: GH, insulin-like growth factor I, and other hormonal responses in beagles.
MK-0677, a spiroindoline sulfonamide, is a novel, orally active GH secretagogue. The effects of MK-0677 on serum GH and other… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE